Vol 9, Supp. A (2018)
Case report
Published online: 2019-06-07
Treatment of patients with chronic myelogenous leukemia with tyrosine kinase inhibitors — skirmishes with side effects of medications
DOI: 10.5603/Hem.2018.0008
Abstract
A 42-year-old woman diagnosed with chronic myelogenous leukemia in the chronic phase in July
2012, initially treated with imatinib followed by dasatinib due to a lack of partial cytogenetic
response after 6 months of treatment. Molecular and cytogenetic response was obtained. In May
and then in August 2013, fluid occurred in both pleural cavities with strong dyspnea. Despite the
reduction of the tyrosine kinase inhibitor, use of diuretics and steroid therapy resolution of the fluid
was not obtained and after the second episode in August 2013 nilotinib was included in the dose
of 800 mg/day. In December 2014, hyperbilirubinemia due to nilotinib was observed. The dose of
the drug was reduced to 400 mg/day with good effect and maintenance of the molecular response.
Keywords: chronic myelogenous leukemiaimatinibdasatinibpleural fluidnilotinibhyperbilirubinemia